On September 17, 2019, the combination therapy of Eisai’s LENVIMA (lenvatinib) and Merck’s KEYTRUDA (pembrolizumab) for the treatment of advanced endometrial carcinoma received simultaneous approvals by Health Canada, the U.S. Food and Drug Administration (FDA), and the Australian Therapeutic Goods Administration.
The joint decision by all three regulatory authorities was the first of its kind and a direct result of the collaborative review process under Project Orbis, a new initiative of the FDA Oncology Center of Excellence. Project Orbis provides the framework for concurrent submission and review of oncology products among international partners despite regulatory divergence, with the goal of facilitating early patient access to innovative oncology products and promoting greater uniformity in the standards of treatment.
In a news release announcing the first action under Project Orbis, the FDA indicated that other countries in addition to Canada and Australia may be involved in future collaborative reviews.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Health Canada seeks input on new draft guidance for co-packaged drug products
On March 18, 2025, Health Canada released a Notice that it is seeking feedback on a draft guidance on co-packaged drug products.Read More -
Canada’s Drug Agency releases 2025 Watch List highlighting AI technologies in health care
On March 25, 2025, Canada’s Drug Agency published its annual Watch List, which identifies technologies with the most potential to transform health systems and shape the future of health care in Canada...Read More -
Health Canada publishes Guide to the precision regulating authorities under the Food and Drugs Act
In March 2025, Health Canada published a Guide to the precision regulating authorities under the Food and Drugs Act.Read More